These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17645587)

  • 1. How can we prevent cardiovascular disease in diabetes.
    Wiklund O; Håversen L; Pettersson C; Hultén LM
    J Intern Med; 2007 Aug; 262(2):199-207. PubMed ID: 17645587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers.
    Toh SA; Rader DJ
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):1007-22. PubMed ID: 18666851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance.
    Brinton EA
    Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and dyslipidaemia.
    Schwartz SL
    Diabetes Obes Metab; 2006 Jul; 8(4):355-64. PubMed ID: 16776742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who needs to care about small, dense low-density lipoproteins?
    Rizzo M; Berneis K
    Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides.
    Barter P
    Atheroscler Suppl; 2006 Aug; 7(4):17-21. PubMed ID: 16828346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atherogenic dyslipidaemia in type 2 diabetes].
    Zozulińska D
    Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S567-71. PubMed ID: 20527378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.